RTP Mobile Logo
Oncology Grand Rounds Series: Part 6 — Lymphomas and Chronic Lymphocytic Leukemia
Released August 2016

Video excerpts from the sixth in a series of 8 integrated symposia held at the 2016 ONS Annual Congress. Featuring perspectives from Dr Michelle A Fanale, Ms Amy Goodrich, Dr John P Leonard and Ms Katey Stephans. (Video Program)

CE Disclosures and Faculty Information

    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

    Hematologic cancers include the lymphomas, the leukemias, multiple myeloma and other related disorders (eg, myelodysplastic syndromes, myeloproliferative diseases) stemming from lymphoid and myeloid progenitor cell lines. Taken together, it is estimated that approximately 171,550 new lymphoid, myeloid and leukemic cancer cases will be identified in the United States in the year 2016 and 58,320 individuals will die from these diseases. Of note, more than 60 drug products are currently labeled for use in the management of hematologic cancers with more than 70 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of liquid and solid tumors. This is particularly true within the realm of Hodgkin and non-Hodgkin lymphoma, including CLL, where substantial progress has been made over the past several years in the development and evaluation of novel agents. Mature clinical trial results have illustrated the efficacy of several new investigational therapies, a number of which have now entered the clinic. Furthermore, enthusiasm is widespread that additional important advancements are on the horizon as other novel agents and strategies have already been associated with impressive clinical benefit.

    This dynamic therapeutic environment clearly highlights the need for all members of the oncology/hematology care team to remain abreast of the ongoing sea change in the management of these diseases, particularly oncology nurses, who play an integral role in the successful delivery of systemic anticancer therapy and the preservation of patient physical and psychosocial well-being. These video proceedings from the sixth part of an 8-part integrated CNE curriculum originally held at the 2016 ONS Annual Congress feature discussions with leading oncology investigators and their nursing counterparts regarding actual patient cases and recent clinical research findings affecting the optimal therapeutic and supportive care for each patient scenario.

    By providing information on the latest research developments in the context of expert perspectives, this CNE activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with lymphomas and CLL.


    • Provide patient-focused education to enhance clinical decision-making regarding the available systemic agents used in the management of indolent and aggressive forms of B-cell NHL, T-cell lymphomas and HL.
    • Formulate supportive care strategies to manage the side effects associated with commonly employed therapeutic interventions for patients with HL, NHL and CLL.
    • Appreciate the FDA approvals of the novel targeted agents ibrutinib, idelalisib and obinutuzumab for the treatment of newly diagnosed and relapsed/refractory (R/R) CLL, and discern how these therapies can be safely integrated into routine clinical practice.
    • Recall available safety and efficacy data with bortezomib, lenalidomide and ibrutinib, and use this information when discussing recommendations regarding the selection and sequencing of therapy for R/R mantle-cell lymphoma.


    CNE credit is no longer available for this issue


    CNE credit is no longer available for this issue

    The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

    CNE credit is no longer available for this issue

    This is a video CNE program.

    CNE credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Michelle A Fanale, MD
    Associate Professor
    Department of Lymphoma and Myeloma at The
    University of Texas MD Anderson Cancer Center
    Houston, Texas

    Consulting Agreements: Merck, Spectrum Pharmaceuticals Inc; Contracted Research: Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc, MedImmune Inc, Merck, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Seattle Genetics, Takeda Oncology; Data and Safety Monitoring Board: Amgen Inc; Honoraria: Merck, Spectrum Pharmaceuticals Inc, Seattle Genetics, Takeda Oncology.

    Amy Goodrich, CRNP-AC
    Nurse Practitioner
    Johns Hopkins Kimmel Cancer Center
    Baltimore, Maryland

    No relevant conflicts of interest to disclose.

    John P Leonard, MD
    Richard T Silver Distinguished Professor of
    Hematology and Medical Oncology
    Associate Dean for Clinical Research
    Weill Cornell Medical College
    New York, New York

    Consulting Agreements: ADC Therapeutics SA, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Eisai Inc, Gilead Sciences Inc, Hospira Inc, MedImmune Inc, Mirati Therapeutics, Novartis Pharmaceuticals Corporation, Pfizer Inc, ProNAi Therapeutics Inc, Seattle Genetics, Teva Oncology.

    Katey Stephans, MS, ANP
    Nurse Practitioner
    Division of Hematologic Malignancies
    Lymphoma and Stem Cell Transplant Programs
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    No relevant conflicts of interest to disclose.

    MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Agendia Inc, Amgen Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Celgene Corporation, Genentech BioOncology, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company and Seattle Genetics.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: August 2016
    Expiration date: August 2017

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):
Video segments: